Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001033224 | SCV001196531 | likely pathogenic | Microcephaly, normal intelligence and immunodeficiency | 2019-12-14 | criteria provided, single submitter | clinical testing | This variant is a gross deletion of the genomic region encompassing exons 15-16 of the NBN gene. The 5' boundary is likely confined to intron 14. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. Deletions of exons 15-16 have been reported in individuals affected with breast cancer and an individual with a family history of breast, ovarian, pancreatic and colon cancer (PMID: 26681312, Invitae). Additionally, a truncating variant in exon 14 of NBN that deletes the amino acids encoded by exons 15 and 16 has been observed in the literature in individuals affected with prostate, bladder and breast cancer and is known to be pathogenic (PMID: 22864661, 26681312). This deletion also removes the ATM interaction domain (amino acids 734-754) of the NBN protein (PMID: 24894818, 21035407), which is important for activating ATM (PMID: 15964794, 15048089). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |